Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

3.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

462
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
462
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robust tauopathy and memory deficits in a mouse model constitutively overexpressing human P301L MAPT.

Neurobiology of disease·2026
Same author

A dating app for extracellular adhesion proteins.

Cell genomics·2026
Same author

Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.

BMJ oncology·2026
Same author

Locally Advanced Conjunctival Squamous Cell Carcinoma not Responsive to Immune Checkpoint Inhibitor Therapy: 3 Cases and a Literature Review.

Ophthalmic plastic and reconstructive surgery·2026
Same author

Intrinsic and non-cell autonomous roles for a neurodevelopmental syndrome-linked transcription factor.

bioRxiv : the preprint server for biology·2026
Same author

A gene expression atlas of a juvenile nervous system.

bioRxiv : the preprint server for biology·2025
Same journal

Bidirectional association between immunobullous diseases and obsessive-compulsive disorder including excoriation disorder.

Archives of dermatological research·2026
Same journal

Diagnosis of immunobullous diseases in underrepresented groups: an all of us database study.

Archives of dermatological research·2026
Same journal

Increased Risk of Melanoma and Basal Cell Carcinoma in Patients with Sjogren's Syndrome: A Nested Case-Control Study.

Archives of dermatological research·2026
Same journal

Vitiligo and Risk of Gastrointestinal Disorders in the United States: A Case-Control Study.

Archives of dermatological research·2026
Same journal

Increased Risk of Sensorineural Hearing Loss in Patients with Vitiligo: A Nested Case-Control Study.

Archives of dermatological research·2026
Same journal

Transgender Individuals' Perspectives on Teledermatology-Based Acne Research.

Archives of dermatological research·2026
See all related articles

Related Experiment Video

Updated: May 25, 2025

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

15.8K

The evolving treatment landscape for CSCC.

David M Miller1,2,3

  • 1Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, USA. dmiller4@mgh.harvard.edu.

Archives of Dermatological Research
|February 26, 2025
PubMed
Summary
This summary is machine-generated.

Immunotherapy is revolutionizing cutaneous squamous cell carcinoma (CSCC) treatment, offering new options for dermatologists. Immune checkpoint inhibitors (ICIs) show promise in advanced CSCC and potentially for high-risk localized disease.

Keywords:
Cutaneous squamous cell carcinomaImmune checkpoint inhibitorImmunotherapy

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.7K
A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

6.7K

Related Experiment Videos

Last Updated: May 25, 2025

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

15.8K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.7K
A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

6.7K

Area of Science:

  • Dermatology
  • Oncology
  • Immunology

Background:

  • Cutaneous squamous cell carcinoma (CSCC) management is evolving.
  • Immunotherapy is transforming CSCC care across all disease stages.
  • Surgery and radiotherapy are standard for localized CSCC, but advanced disease requires systemic options.

Purpose of the Study:

  • To review the evolving treatment landscape of CSCC.
  • To highlight the role of immunotherapy, including immune checkpoint inhibitors (ICIs), in CSCC management.
  • To discuss emerging applications of ICIs in dermatology.

Main Methods:

  • Review of current literature on CSCC treatment.
  • Analysis of the impact of immunotherapy on CSCC.
  • Discussion of neoadjuvant, adjuvant, and intralesional ICI strategies.
  • Exploration of anti-PD-1 therapy for actinic neoplasia syndrome.

Main Results:

  • Immune checkpoint inhibitors (ICIs) provide durable responses and survival benefits in advanced CSCC.
  • Emerging ICI strategies (neoadjuvant, adjuvant, intralesional) may improve outcomes for high-risk, resectable CSCC.
  • Anti-PD-1 therapy shows potential for preventing actinic neoplasia syndrome, requiring further investigation.

Conclusions:

  • Immunotherapy is expanding the role of dermatologists in CSCC management.
  • Dermatologists must be prepared to manage immunotherapy-related adverse events through collaboration and training.
  • Continued research and thoughtful application of immunotherapies are crucial for optimizing CSCC care.